ABVC BioPharma, Inc. (ABVC) Total liabilities 2018–2025
ABVC BioPharma, Inc. (ABVC) total liabilities at each fiscal year-end, per SEC filings.
$7.8MFY2025 · since FY2018: $11.3M → $7.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $7.8M | +13.9% |
| FY2024 | $6.8M | +4.4% |
| FY2023 | $6.5M | +3.0% |
| FY2022 | $6.3M | +31.4% |
| FY2021 | $4.8M | -46.0% |
| FY2020 | $8.9M | +26.8% |
| FY2019 | $7.1M | -37.5% |
| FY2018 | $11.3M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More ABVC financial trends
ABVC RevenueABVC Net incomeABVC Net marginABVC Gross profitABVC Gross marginABVC Operating incomeABVC Operating marginABVC Operating cash flowABVC Free cash flowABVC Capital expendituresABVC Return on equityABVC Stock buybacksABVC Dividends paidABVC Total assetsABVC Shareholders’ equityABVC overview →